Introduction
Peptide therapy has emerged as one of the most exciting frontiers in hormone optimization medicine. Practitioners who add evidence-supported peptide protocols to their hormone clinics can offer a broader range of services, differentiate their practice, and deliver meaningful clinical benefits to patients who want to go beyond traditional hormone replacement. This guide introduces the key peptide therapies gaining traction in hormone optimization practices.
What Are Peptides?
Peptides are short chains of amino acids that act as biological signaling molecules in the body. Unlike hormones—which are produced by endocrine glands and have broad systemic effects—peptides typically act more locally or on specific receptor pathways. In clinical medicine, therapeutic peptides are used to stimulate growth hormone release, promote tissue healing, enhance sexual function, support immune function, and improve cognitive performance, among other applications.
Growth Hormone Secretagogues: Sermorelin, CJC-1295, and Ipamorelin
Growth hormone declines with age, contributing to decreased muscle mass, increased adiposity, reduced energy, and impaired recovery. Growth hormone secretagogues (GHS) stimulate the pituitary to produce more endogenous growth hormone. The most widely used in hormone clinics include Sermorelin (a GHRH analog), CJC-1295 (a longer-acting GHRH analog), and Ipamorelin (a ghrelin receptor agonist). These are often prescribed in combination (CJC-1295 + Ipamorelin is a common protocol) and administered via subcutaneous injection before bedtime. Benefits include improved body composition, sleep quality, recovery, and energy.
BPC-157: Tissue Healing and Gut Health
BPC-157 (Body Protection Compound 157) is derived from a protein found in gastric juice. It has been shown in animal studies—and experienced anecdotally by thousands of patients—to accelerate healing of tendons, ligaments, muscle, and gut mucosa. It is often prescribed to patients recovering from injuries or with GI conditions. BPC-157 is compounded as a subcutaneous injectable or oral capsule.
PT-141 (Bremelanotide) for Sexual Function
PT-141 is a melanocortin receptor agonist that acts centrally (in the brain) to promote sexual arousal in both men and women. Unlike PDE5 inhibitors (Viagra, Cialis), which work peripherally on blood flow, PT-141 works on the neurological pathway of desire. It is particularly valuable for patients with low libido that has not responded to hormone optimization alone. PT-141 is administered subcutaneously 45-60 minutes before sexual activity.
Regulatory Status and Prescribing Considerations
The regulatory landscape for peptides is evolving rapidly. Many peptides are compounded medications without FDA approval for specific indications. The FDA has placed some peptides on lists that restrict their compounding. Always check current FDA guidance and your state’s compounding pharmacy regulations before prescribing peptides. Stay current with this rapidly changing regulatory environment.
Integrating Peptides Into Your Hormone Clinic
Add peptide therapy as a natural extension of your hormone optimization services. Introduce peptides to appropriate patients as complementary tools that enhance the results of their hormone therapy. Develop clear protocols, informed consent documents, and monitoring parameters for each peptide you offer. Peptide therapy adds meaningful revenue and clinical differentiation to your hormone optimization practice.
Conclusion
Peptide therapy represents a compelling frontier for hormone optimization practitioners. As evidence accumulates and patient interest grows, practices that develop expertise in evidence-supported peptide protocols will be positioned as comprehensive optimization centers—not merely prescription dispensaries. Invest in the education needed to use these tools safely and effectively.